(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...
Stats | |
---|---|
今日成交量 | 2 928.00 |
平均成交量 | 3 599.00 |
市值 | 114.45B |
EPS | €2.55 ( 2023-10-27 ) |
Last Dividend | €3.56 ( 2023-05-30 ) |
Next Dividend | €0 ( N/A ) |
P/E | 21.27 |
ATR14 | €0.171 (0.19%) |
音量 相关性
Sanofi SA 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Sanofi SA 相关性 - 货币/商品
Sanofi SA 财务报表
Annual | 2023 |
营收: | €43.07B |
毛利润: | €28.83B (66.95 %) |
EPS: | €4.31 |
FY | 2023 |
营收: | €43.07B |
毛利润: | €28.83B (66.95 %) |
EPS: | €4.31 |
FY | 2022 |
营收: | €45.39B |
毛利润: | €31.69B (69.83 %) |
EPS: | €6.69 |
FY | 2021 |
营收: | €39.18B |
毛利润: | €26.92B (68.72 %) |
EPS: | €4.96 |
Financial Reports:
No articles found.
Sanofi SA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€3.56 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €2.07 | 2008-05-16 |
Last Dividend | €3.56 | 2023-05-30 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | €45.47 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.29 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.67 | |
Div. Directional Score | 8.77 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TLX.DE | Ex Dividend Junior | 2023-05-05 | Annually | 0 | 0.00% | |
DUE.DE | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% | |
MTX.DE | Ex Dividend Junior | 2023-05-12 | Annually | 0 | 0.00% | |
ABL.DE | Ex Dividend Knight | 2023-10-12 | Quarterly | 0 | 0.00% | |
WCH.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
FPE3.DE | Ex Dividend Knight | 2023-05-04 | Annually | 0 | 0.00% | |
PAT.DE | Ex Dividend Junior | 2023-05-26 | Sporadic | 0 | 0.00% | |
AXA.DE | Ex Dividend Junior | 2023-05-08 | Sporadic | 0 | 0.00% | |
HHFA.DE | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
S9I.DE | Ex Dividend Knight | 2023-05-15 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.139 | 1.500 | 7.23 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0627 | 1.200 | 7.91 | 9.49 | [0 - 0.3] |
returnOnEquityTTM | 0.108 | 1.500 | 9.92 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.277 | 0.800 | 8.62 | 6.89 | [1 - 3] |
quickRatioTTM | 0.390 | 0.800 | -2.41 | -1.928 | [0.8 - 2.5] |
cashRatioTTM | 0.363 | 1.500 | 9.10 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.132 | -1.500 | 7.80 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 7.43 | 1.000 | 8.36 | 8.36 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.20 | 2.00 | 7.27 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.60 | 2.00 | 7.20 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.225 | -1.500 | 9.10 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.678 | 1.000 | 2.03 | 2.03 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.231 | 1.000 | 7.39 | 7.39 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.615 | 1.000 | 7.69 | 7.69 | [0.2 - 2] |
assetTurnoverTTM | 0.452 | 0.800 | -0.318 | -0.255 | [0.5 - 2] |
Total Score | 10.87 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.44 | 1.000 | 8.64 | 0 | [1 - 100] |
returnOnEquityTTM | 0.108 | 2.50 | 9.95 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.60 | 2.00 | 8.13 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.89 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.20 | 2.00 | 7.27 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.659 | 1.500 | 8.94 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.180 | 1.000 | 8.01 | 0 | [0.1 - 0.5] |
Total Score | 6.67 |
Sanofi SA
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。